Ubs Oconnor LLC Travere Therapeutics, Inc. Transaction History
Ubs Oconnor LLC
- $1.46 Billion
- Q3 2024
A detailed history of Ubs Oconnor LLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 120,000 shares of TVTX stock, worth $2.55 Million. This represents 0.12% of its overall portfolio holdings.
Number of Shares
120,000Holding current value
$2.55 Million% of portfolio
0.12%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding TVTX
# of Institutions
199Shares Held
85MCall Options Held
776KPut Options Held
912K-
Armistice Capital, LLC New York, NY7.65MShares$162 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$162 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$146 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$99.4 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$92.1 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.36B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...